11 August 2022 · Trastuzumab products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Thiotepa products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Hydrocortisone products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Hydromorphone products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Topotecan products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Amikacin products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Etoposide products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Ziconotide products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Levobupivacaine products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Rituximab products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration